文献速递心律失常

肥胖与糖尿病对房颤早期节律控制疗效的影响:EAST-AFNET 4 二次分析

Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该研究为EAST-AFNET 4随机临床试验的预设二次分析,评估体重指数(BMI)与糖尿病对早期节律控制疗效的影响。结果显示,无论有无肥胖或糖尿病,早期节律控制对主要复合终点(心血管死亡、卒中、心衰住院或急性冠脉综合征)的疗效与安全性均保持一致,交互作用均不显著。

核心结论

  • 在EAST-AFNET 4中,早期节律控制疗法在伴或不伴糖尿病及伴或不伴肥胖的患者中均保持有效性和安全性。

研究设计与样本

  • EAST-AFNET 4为国际、研究者发起、平行组、开放、盲法终点评估的随机临床试验,在11个欧洲国家开展。
  • 纳入早期房颤(入组前诊断≤1年)且合并心血管疾病的患者,本分析为预设二次分析,采用意向性治疗人群。
  • 共1086例肥胖患者(BMI≥30,平均BMI 34.5)和1690例非肥胖患者(BMI<30,平均BMI 25.9);总体平均年龄70岁,女性1293例(46.6%)。

主要发现

  • 肥胖患者更年轻(平均年龄68 vs 72岁)且非阵发性房颤比例更高(31% vs 24%),平均CHA2DS2-VASc评分无差异(3.4 vs 3.3)。

临床怎么用

  • 对于合并肥胖或糖尿病的早期房颤患者,早期节律控制策略的疗效与安全性不受影响,可考虑应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The EAST-AFNET 4 randomized clinical trial demonstrated that early rhythm control therapy added to anticoagulation therapy and therapy of concomitant conditions reduces the primary composite outcome of cardiovascular death, stroke, hospitalization because of heart failure, or acute coronary syndrome compared to usual care. However, the impact of body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) and diabetes on outcomes in EAST-AFNET 4 is not known. OBJECTIVE: To assess the effects of BMI and diabetes on outcomes in EAST-AFNET 4. DESIGN, SETTING, AND PARTICIPANTS: EAST-AFNET 4 is an international, investigator-initiated, parallel-group, open, blinded outcome assessment randomized clinical trial conducted in 11 European countries. Patients who had early atrial fibrillation (AF, diagnosed ≤1 year before enrollment) and cardiovascular conditions were eligible for inclusion. The current analysis is a prespecified secondary analysis of the EAST-AFNET 4 trial performed in the final, locked dataset assigning patients to therapy group on the basis of randomization (intention-to-treat population). EAST-AFNET 4 was conducted from June 2010 to May 2020, and this secondary analysis of the final locked data base was performed in 2024. INTERVENTION: EAST-AFNET 4 randomly assigned patients to either early rhythm control or usual care. MAIN OUTCOMES AND MEASURE: The primary outcome of this analysis and the EAST-AFNET 4 trial is a composite of cardiovascular death, stroke, hospitalization because of heart failure, or acute coronary syndrome. RESULTS: There were 1086 patients with obesity (BMI ≥30; mean [SD] BMI 34.5 [4.2]) and 1690 patients without obesity (BMI <30; mean [SD] BMI 25.9 [2.6]). Overall mean patient age was 70 years, and 1293 patients (46.6%) were female. Patients with obesity were younger (mean [SD] age, 68 [8.6] vs 72 [7.7] years) and had more frequently nonparoxysmal AF patterns (31% vs 24%) than patients without obesity. There was no difference in mean (SD) CHA2DS2-VASc score (3.4 [1.3] vs 3.3 [1.3]). Obesity did not change the effect of early rhythm control therapy on the first primary outcome (hazard rate point estimates: BMI <30, 0.84; BMI ≥30, 0.69; P for interaction = .22). Patients with diabetes were younger (mean [SD] age, 69 [8.6] vs 71 [8.2] years; P = .001) and had a higher mean CHA2DS2-VASC score (4.06 vs 3.11; P < .001). Diabetes did not interact with the treatment effect of early rhythm control (diabetes: hazard ratio [HR], 0.77; 95% CI, 0.57-1.05 vs no diabetes: HR, 0.78; 95% CI, 0.64-0.96; P for interaction = .93). There was no difference in safety outcomes between patients with and without diabetes (64 of 351 patients [18.2%] vs 167 of 1039 patients [16.1%]; P for interaction = .99). CONCLUSIONS AND RELEVANCE: This secondary analysis of the EAST-AFNET 4 randomized clinical trial shows that early rhythm control therapy retains its effectiveness and safety in patients with and without diabetes and patients with and without obesity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01288352.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Metzner, Willems, Borof, et al. Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40737012. doi:10.1001/jamacardio.2025.2374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。